What is Benitec Biopharma Inc.'s market cap?

Benitec Biopharma Inc. (BNTC) has a market capitalization of $397.8M and trades on NASDAQ.

Who are Benitec Biopharma Inc.'s competitors?

Benitec Biopharma Inc.'s key competitors include Sarepta Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.

What subsidiaries does Benitec Biopharma Inc. have?

Benitec Biopharma Inc.'s subsidiaries include Benitec Biopharma Limited.

Where is Benitec Biopharma Inc. headquartered?

Benitec Biopharma Inc. is headquartered in United States of America and employs approximately 16 people. It has been publicly traded since 2012.

Benitec Biopharma Inc.

BNTC

Benitec Biopharma is a clinical-stage biotechnology company focused on developing a proprietary therapeutic platform that combines RNA interference with gene therapy.

Market cap

$397.82M+34.7%

Table of contents

Earnings

Q1 2026 report

May 14, 2026

EPS-$0.24Beat by $0.03

Read the full report

Next report

Sep 28, 2026 (in 2 months)

EPS estimate-$0.25

Competitors

By market cap

ALN

Alnylam Pharmaceuticals$37.2B-12.2%

Arrowhead Research$12.0B+439%

uniQure$2.6B+220%

Sarepta Therapeutics, Inc.$1.7B+23.2%

Benitec Biopharma Inc.$397.8M+37.5%

enGene Therapeutics Inc. $117.9M-36.6%

Boundless Bio, Inc.$55.7M+101%

Xenetic Biosciences$5.7M+2.0%

By revenue growth

ALN

Alnylam Pharmaceuticals+82.6%

uniQure+30.2%

Arrowhead Research+14.1%

Sarepta Therapeutics, Inc.+9.9%

By net margin

ALN

Alnylam Pharmaceuticals11.72%+21.5pp

Sarepta Therapeutics, Inc.4.64%-38.4pp

Arrowhead Research-48.38%-22.0pp

uniQure-1,350.73%+37.3pp

Profile

Benitec Biopharma is a clinical-stage biotechnology company focused on developing a proprietary therapeutic platform that combines RNA interference with gene therapy. The company's core value proposition lies in its 'DNA-directed RNA interference' (ddRNAi) technology, designed to provide sustained silencing of disease-causing genes through a single administration.

Competitive position

Benitec is a specialized player in the gene silencing space, competing against larger biopharmaceutical firms with significantly greater clinical development and commercialization resources.

GeographiesUnited States, Australia, Global

Customer segmentsBiopharmaceutical companies, Clinical research organizations

Business modelR&D intensive, IP Licensing

SuppliersAcademic research institutions, AAV vector patent holders, Contract manufacturing organizations, Specialized laboratory equipment providers

CustomersLarge-cap pharmaceutical partners, Clinical trial participants, Specialized medical centers

CountryUnited States of America

Listed2012

Employees16.0

CEOJerel A. Banks

SectorHealthcare

IndustryBiotechnology

Websitebenitec.com

FilingsSEC EDGAR

Questions, answered.

What is Benitec Biopharma Inc.'s market cap?: Benitec Biopharma Inc. (BNTC) has a market capitalization of $397.8M and trades on NASDAQ.
Who are Benitec Biopharma Inc.'s competitors?: Benitec Biopharma Inc.'s key competitors include Sarepta Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.
What subsidiaries does Benitec Biopharma Inc. have?: Benitec Biopharma Inc.'s subsidiaries include Benitec Biopharma Limited.
Where is Benitec Biopharma Inc. headquartered?: Benitec Biopharma Inc. is headquartered in United States of America and employs approximately 16 people. It has been publicly traded since 2012.